en · de · es · fr · pt
analytical-notes.peptides6823.com › Data › Cjc-1295 Background And Mechanism — What the Evidence Shows

Cjc-1295 Background And Mechanism — What the Evidence Shows

By Editorial Desk · published 2025-09-02 · last reviewed 2025-10-21 · Data

If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-10-21. Numbers and descriptions here follow the published literature rather than marketing material.

CJC-1295 Background and Mechanism

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Handling Storage and Quality Control

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight (with DAC)~3647 DaCalculated from the full amino acid sequence
Molecular weight (without DAC)~3368 DaMod GRF(1-29) variant
AppearanceWhite lyophilized powderTypical form supplied for research
SolubilitySoluble in waterDissolves in aqueous buffers
Receptor targetGHRH receptorExpressed on pituitary somatotroph cells

Background and Molecular Features

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

Related pages on this site

Persistence, Stability and Measurement

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Compound Identity and Development History

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Notes from published material

== History == Efficacy was evaluated in the LUMINOSITY study (NCT03539536), a multi-center, open label, multi-cohort trial. The trial included 84 participants with epidermal growth factor receptor wild-type, non-squamous non-small cell lung cancer with high c-Met protein overexpression who had received prior systemic therapy. The benefits and side effects of telisotuzumab vedotin were evaluated in one clinical trial of 168 participants with non-squamous, EGFR wild-type non-small cell lung cancer with high c-Met protein overexpression who had received one to three prior systemic treatments. The US Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin based predominantly on evidence from one clinical trial (LUMINOSITY/NCT03539536) of 168 participants with non-squamous, epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer with c Met protein overexpression who had received prior systemic therapy, including 19 participants from the United States. The trial was conducted at 119 sites across 23 countries in North America, Europe, Asia, the Middle East, and Oceania. There were 84 participants with non-squamous, EGFR wild-type non-small cell lung cancer with high c-Met protein overexpression who had received prior systemic therapy. The FDA granted the application for telisotuzumab vedotin priority review and breakthrough therapy designations.

You must know that, for my part, there would be none, determined as I am to leave the command in this next Congress, but who can mitigate the ambition of our leaders and the fear of inequality among the lowly people? Don't you think that England would be jealous of the choice made in a Bourbon? How much would not be opposed by all the new American states, and the United States that seem destined by Providence to plague America with miseries in the name of Liberty? It seems to me that I already see a general conspiracy against this poor Colombia, already too envied by all the Republics America has. All the presses would be in motion calling for a new crusade against the accomplices of treason against freedom, addicts of the Bourbons and violators of the American system. In the South, the Peruvians would ignite the flame of discord; by the Isthmus those of Guatemala and Mexico, and by the Antilles the Americans and the liberals of all parts. Santo Domingo would not stay idle and call his brothers to make common cause against a prince of France. They would all become enemies without Europe doing anything to support us, because the New World is not worth the expense of a Holy Alliance; At least, we have reason to judge so, due to the indifference with which we have been seen to undertake and fight for the emancipation of half the world, which very soon will be the most productive source of European prosperity.

== Hospital Facilities == .Theodor Bilharz research Institute Hospital is a tertiary hospital in Waraq El-Hadar, Giza, Egypt. · Six surgical theatres .Three ICU units ( 11 beds general medical ICU, 4 beds Surgical post-operative and 12 beds Hepatic ICU) .240 beds of Hepatology, Nephrology, General Medicine, Urosurgery, General Surgery, Intensive Care Unit. .Diagnostic Radiology department. . Interventional Radiology Unit. · Endoscopic facilities (gastroduodenoscopy, colonoscopy and ERCP) with ultrasonography and Doppler-electrocardiography. · Laparoscopic facilities for diagnostic and therapeutic purposes. · Minimal invasive urosurgery utilizing ureterorenoscopy; nephroscope and cystoscope, under fluoroscopic and endo-camera guidance. · Blood gas monitoring with estimation of serum electrolytes. · Fluoroscopy guided angio-table. · Twenty machines for haemodialysis. . Blood bank and various laboratories

=== Software === There are many free software packages available for visualization and mining of imaging mass spectrometry data. Converters from Thermo Fisher format, Analyze format, GRD format and Bruker format to imzML format were developed by the Computis project. Some software modules are also available for viewing mass spectrometry images in imzML format: Biomap (Novartis, free), Datacube Explorer (AMOLF, free), EasyMSI (CEA), Mirion (JLU), MSiReader (NCSU, free) and SpectralAnalysis. For processing .imzML files with the free statistical and graphics language R, a collection of R scripts is available, which permits parallel-processing of large files on a local computer, a remote cluster or on the Amazon cloud. Another free statistical package for processing imzML and Analyze 7.5 data in R exists, Cardinal. SPUTNIK is an R package containing various filters to remove peaks characterized by an uncorrelated spatial distribution with the sample location or spatial randomness. The Python ecosystem provides a range of specialized libraries for processing mass spectrometry data, serving distinct analytical needs. PyOpenMS offers Python bindings for the C++ OpenMS library, facilitating operations such as signal processing, feature finding, and quantification. In contrast, pymzML is a lightweight parser optimized specifically for rapid data extraction and interaction with mzML files.

Sources: en.wikipedia.org

Background from the literature

== Life and career == Aylward was born and raised in Seattle, Washington. He attended St. Joseph's Grade school and went on to Prep High School, but graduated from Garfield High School in 1965. He graduated from the Professional Actor's Training Program at the University of Washington in 1970. Beginning his acting career in Seattle, he was also one of the founders, in 1973, of Empty Space Theatre there. He worked regularly as a company member of the Seattle Repertory Theatre. He appeared in dramas by David Mamet, Arthur Miller and Tennessee Williams. Carol Flynt, co-producer of ER, first offered him an audition after seeing him in a 1996 production of Psychopathia Sexualis at the Mark Taper Forum in Los Angeles. He went on to play the recurring role of Dr. Donald Anspaugh on ER from 1996 to 2008. He also had a recurring role as former DNC chairman Barry Goodwin on The West Wing from 2005 to 2006. He also provided the voice of Dr. Arne Magnusson in the 2007 video game Half-Life 2: Episode Two. Aylward appeared in numerous television shows, including Northern Exposure, 3rd Rock from the Sun, The Practice, Law & Order and Mad Men. His film roles included Three Fugitives (1989), Teenage Mutant Ninja Turtles III (1993), Buddy (1997), Armageddon (1998), Thirteen Days (2000), and the HBO films From the Earth to the Moon (1998) and Path to War (2002). He played Father Edward Devine in the 2020 sports drama movie The Way Back. Aylward died in Seattle on May 16, 2022, at the age of 75.

== Clinical significance == Urothelium is susceptible to carcinoma. Because the bladder is in contact with urine for extended periods, chemicals that become concentrated in the urine can cause bladder cancer. For example, cigarette smoking leads to the concentration of carcinogens in the urine and is a leading cause of bladder cancer. Aristolochic acid, a compound found in plants of the family Aristolochiaceae, also causes DNA mutations and is a cause of liver, urothelial and bladder cancers. Occupational exposure to certain chemicals is also a risk factor for bladder cancer. This can include aromatic amines (aniline dye), polycyclic aromatic hydrocarbons, and diesel engine exhaust.

When tungsten filaments were introduced, about 50 million lamp sockets existed in the US. In 1914, 88.5 million lamps were used, (only 15% with carbon filaments), and by 1945, annual sales of lamps were 795 million (more than 5 lamps per person per year).

Sources: en.wikipedia.org

Further detail

=== Regulation of respiration === Carbon dioxide is one of the mediators of local autoregulation of blood supply. If its concentration is high, the capillaries expand to allow a greater blood flow to that tissue. Bicarbonate ions are crucial for regulating blood pH. A person's breathing rate influences the level of CO2 in their blood. Breathing that is too slow or shallow causes respiratory acidosis, while breathing that is too rapid leads to hyperventilation, which can cause respiratory alkalosis. Although the body requires oxygen for metabolism, low oxygen levels normally do not stimulate breathing. Rather, breathing is stimulated by higher carbon dioxide levels. As a result, breathing low-pressure air or a gas mixture with no oxygen at all (such as pure nitrogen) can lead to loss of consciousness without ever experiencing air hunger. This is especially perilous for high-altitude fighter pilots. It is also why flight attendants instruct passengers, in case of loss of cabin pressure, to apply the oxygen mask to themselves first before helping others; otherwise, one risks losing consciousness. The respiratory centers try to maintain an arterial CO2 pressure of 40 mmHg. With intentional hyperventilation, the CO2 content of arterial blood may be lowered to 10–20 mmHg (the oxygen content of the blood is little affected), and the respiratory drive is diminished. This is why one can hold one's breath longer after hyperventilating than without hyperventilating.

c-MET may interact with FoxM1, a molecule important in the cell cycle, as FOXM1 levels decrease when c-MET is not present. Additionally, c-MET may interact with p27 as the protein levels increase when c-MET is not present. Another hypothesis says that c-MET may control β-cell apoptosis because a lack of c-MET causes increased cell death, but the signaling mechanisms have not been elucidated. Although the mechanism of HGF/c-MET control of gestational diabetes is not yet well understood, there is a strong correlation between the signaling pathway and the inability to produce an adequate amount of insulin during pregnancy, and thus it may be the target for future diabetic therapies. Because glucose travels across the placenta (through diffusion facilitated by GLUT1 carrier), which is located in the syncytiotrophoblast on both the microvilli and basal membranes, these membranes may be the rate-limiting step in placental glucose transport. There is a two- to three-fold increase in the expression of syncytiotrophoblast glucose transporters with advancing gestation. Finally, the role of GLUT3/GLUT4 transport remains speculative. If the untreated gestational diabetes fetus is exposed to consistently higher glucose levels, this leads to increased fetal levels of insulin (insulin itself cannot cross the placenta). The growth-stimulating effects of insulin can lead to excessive growth and a large body (macrosomia).

== Early life == Melksham grew up in Glenroy, Victoria; as a junior, he played for the Oak Park Football Club in the Essendon District Football League, and attended Penleigh and Essendon Grammar School. Joining the Calder Cannons under 18 side in the TAC Cup as a bottom-aged player in 2007 at sixteen years of age, a bout of osteitis pubis set in towards the end of the year, which hampered his summer training and saw him miss several games during the 2008 season. In 2008, he was awarded a scholarship with the Australian Institute of Sport (AIS) as part of AIS-AFL Academy in their eleventh intake. Melksham spent his final year as a junior playing for the Calder Cannons, which saw the club win their fifth premiership when they defeated the Dandenong Stringrays by fourteen points in the grand final. His performance in the grand final saw him adjudged the best on ground and he was awarded the TAC Medal after he recorded twenty-four disposals and seven inside-50s. He received mid-year state honours when he represented Vic Metro in the 2009 AFL Under 18 Championships and prior to the start of the competition he was labelled by The Age journalist, Emma Quayle, as one of the "players to watch" during the championships. He averaged eighteen disposals during the championships and ranked second overall for Vic Metro in clearances and score assists, behind eventual number one draft pick, Tom Scully. After a slow start to the year, he had a strong finish to the year, which elevated his draft chances to inside the top ten.

=== Pharmacokinetics === Metandienone has high oral bioavailability. It has very low affinity for human serum sex hormone-binding globulin (SHBG), about 10% of that of testosterone and 2% of that of DHT. The drug is metabolized in the liver by 6β-hydroxylation, 3α- and 3β-oxidation, 5β-reduction, 17-epimerization, and conjugation among other reactions. Unlike methyltestosterone, owing to the presence of its C1(2) double bond, metandienone does not produce 5α-reduced metabolites. The elimination half-life of metandienone is about 3 to 6 hours. It is eliminated in the urine.

Sources: en.wikipedia.org

Frequently asked questions

What distinguishes CJC-1295 from natural GHRH?

The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.

Why does the DAC group matter?

The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.

Is CJC-1295 an approved medicine?

It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.

How should the lyophilized powder be stored?

The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.

Network